Helius Medical (HSDT) Technologies announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare. “The recent reimbursement approvals from two major commercial healthcare payers, with a third underway, mark significant milestones for Helius and the MS community,” said Dane Andreeff, Helius’ President and Chief Executive Officer. “We are actively pursuing broader in-network coverage for PoNS at list price from major commercial payers, while continuing to negotiate reimbursement on a case-by-case basis. We expect to continue our efforts in expanding patient access and ensuring consistent reimbursement as we work to align commercial payments with the rates currently offered by the VA/DoD at $26,228. At the same time, we remain firmly committed to supporting individuals with MS who rely on Medicare for PoNS treatment and believe this, along with other 3rd party payer reimbursement decisions will benefit our continued efforts to secure fair and adequate reimbursement by CMS for the PoNS system.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSDT:
- Helius Medical Technologies Achieves Nasdaq Bid Price Compliance
- Helius Medical compliant with Nasdaq bid price rule listing criteria
- Helius Medical files to sell 3.45M shares of common stock
- Helius Medical Approves Reverse Stock Split and Share Increase
- Helius Medical highlights results of new study on PoNS